Magic Touch SCB
Sirolimus Coated Balloon Catheter
Technical Specification
Drug / Exipient | |
Drug | Sirolimus |
Drug Dose | 1.27 μg/mm2 |
Drug Carrier | Phospholipid |
Balloon | |
Balloon Material | Polyamide |
Cathether Design | RX/Monorail |
No. of folds | 3** |
Compliance | Semi-compliant |
** 2 folds in 1.50 mm diameter
Delivery System | |
Shaft Diameter - Proximal | RX/Monorail |
Shaft Diameter - Distal | 1.95 F |
Usable Catheter Length | 2.67 F |
Tip Profile | 0.016” |
Nominal Pressure | 8 bar |
Rated Burst Pressure | 14 bar* |
Guiding Catheter Compatibility | 6F |
Guidewire Compatibility | 0.014” maximum recommended |
Crossing profile (varies with size) | 0.029” |
We highly recommend preparing the vessel bed before treatment with MagicTouch – SCB
*Do Not Exceed RBP
*The above diagram is just an illustration of the product.
Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product
labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.
MAGICTOUCH SCB
MagicTouch – SCB is a Sirolimus Drug Coated Balloon catheter for the treatment of the coronary arteries;
intended for treating In-Stent Restenosis, Small Vessels, Bifurcations lesions and De-Novo lesions.
DE-NOVO LESIONS
Concept of treating with leaving Nothing behind in patients with highly susceptible restenosis rate due to inherent disease conditions and comorbid conditions.
BIFURCATION LESIONS
Addresses the issue of metal to artery ratio by allowing one stent technique and less complications in side branch.
IN-STENT RESTENOSIS
Addresses the issue of restenosis by homogenous drug distribution without further increasing metal load in diffuse, focal and edge stenosis.
SMALL VESSELS
Helps in treating challenging anatomies in small diameter without loosing lumen diameter.
UNIQUE COATING TECHNOLOGY
MagicTouch – SCB is developed with Nanolute Technology which possesses unique circumferential coating technology that facilitates homogeneous drug distribution to target lesions.
COATING
Circumferential Coating is
performed under Low Pressure inflation
leading to 100% surface area coating
REFOLDING
۳ Folds
INFLATION
Homogeneous Drug Delivery
due to Circumferential Coating
NANOLUTE TECHNOLOGY
PHARMACOKINETIC STUDY
In ISR Lesion*
SIROLIMUS DISTRIBUTION STUDY
DTF labelled Sirolimus was used to assess the drug distribution following DCB treatment*
A: Adventitia; EEL: External Elastic Lamina; IEL: Internal Elastic Lamina; L: Lumen; M: Media *EuroIntervention. 2013 May 20;9(1): 148-56